WASHINGTON (TIP): A first-of-its-kind implant to treat obesity that curbs appetite by electrically stimulating stomach ne8rves has been approved in the US.
The Maestro Rechargeable System is approved to treat patients aged 18 and above who have not been able to lose weight with a weight loss programme, and who have a body mass index of 35 to 45 with at least one other obesity-linked condition, like type-2 diabetes.
The US Food and Drug Administration (FDA) approved the implant for certain obese adults, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness. BMI, which measures body fat based on an individual’s weight and height, is used to define obesity categories. According to the Centres for Disease Control and Prevention, more than one-third of all US adults are obese, and people with obesity are at increased risk of heart disease, stroke, type-2 diabetes and certain kinds of cancer. “Medical devices can help physicians and patients develop comprehensive obesity treatment plans,” said William Maisel, deputy director for science and chief scientist at FDA’s Centre for Devices and Radiological Health. The system consists of a rechargeable electrical pulse generator, wire leads and electrodes implanted surgically into the abdomen.
It works by sending intermittent electrical pulses to the trunks in the abdominal va8gus nerve, which is involved in regulating stomach emptying and signalling to the brain that the stomach feels empty or full. Although it is known that the electric stimulation blocks nerve activity between the brain and the stomach, the specific mechanisms for we8ight loss due to use of the %device are unknown.